LY2216684
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Depressive Disorder, Major
Conditions
Depressive Disorder, Major
Trial Timeline
Jul 1, 2011 → Aug 1, 2011
NCT ID
NCT01389765About LY2216684
LY2216684 is a phase 1 stage product being developed by Eli Lilly for Depressive Disorder, Major. The current trial status is completed. This product is registered under clinical trial identifier NCT01389765. Target conditions include Depressive Disorder, Major.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01389765 | Phase 1 | Completed |
| NCT01241435 | Phase 1 | Completed |
Competing Products
20 competing products in Depressive Disorder, Major
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| duloxetine | Eli Lilly | Pre-clinical | 23 |
| Duloxetine Hydrochloride | Eli Lilly | Pre-clinical | 23 |
| LY2216684 | Eli Lilly | Phase 1 | 33 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |
| LY2216684 + Digoxin | Eli Lilly | Phase 1 | 33 |
| Duloxetine + Paroxetine | Eli Lilly | Phase 3 | 77 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 77 |
| LY2216684 + Placebo + Escitalopram | Eli Lilly | Phase 2 | 52 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| quetiapine extended release (XR) + Placebo | Astellas Pharma | Phase 2 | 52 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| Mirtazapine Tablets | Sun Pharmaceutical | Approved | 85 |
| Duloxetine Hydrochloride | Shionogi | Phase 3 | 77 |
| Duloxetine Hydrochloride + Placebo | Shionogi | Phase 3 | 77 |
| ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1 | Ono Pharmaceutical | Phase 2 | 52 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Pramipexole ER + Escitalopram | Cipla | Phase 2 | 52 |
| LY2216684 + Sertraline | Eli Lilly | Phase 1 | 33 |